CTIS2023-504900-28-00进行中（未招募）1 期
A Phase 1/2 Clinical Study of Intravenous Gene Transfer with an AAVrh10 Vector Expressing GALC in Krabbe Subjects Receiving Hematopoietic Stem Cell Transplantation (RESKUE) - FBX-101-RESKUE
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Diagnosis of infantile Krabbe disease, characterized by the following criteria: a. Galactocerebrosidase (GALC) activity levels in leukocytes compatible with the diagnosis of Krabbe disease; AND AT LEAST ONE OF THE FOLLOWING: b. Elevated psychosine levels predictive of infantile onset by DBS; OR c. Imaging or neurophysiological findings consistent with Krabbe disease (CSF, MRI, NCV, ABR, refer to Addendum 1); OR, d. Two GALC mutations predictive to result in infantile onset phenotype, Age at the time of screening: 1 day to 12 months, Participant has been deemed eligible for treatment with HSCT (standard of care) and a fully myeloablative reduced intensity/toxicity conditioning regimen (RIC/RTC) is/has been used, Participant’s parents or legal guardian consents to participate in the study and provides informed consent according to IRB guidelines prior to any study procedures being performed, Parent(s) and/or legal guardian able to comply with the clinical protocol, Participant must have adequate organ function at time of screening or evaluation as measured by: a. Creatinine =1.5× of upper limit of age appropriate normal and creatinine clearance = 60 mL/min/1.73 m2; b. Hepatic transaminases (ALT/AST) = 2 x age related upper limit of normal; c. Ejection fraction of > 50% by echocardiogram or other appropriate study without evidence of pulmonary hypertension; d. Pulmonary evaluation testing demonstrating resting pulse oximeter > 95% on room air; e. Coagulation tests within 110% of normal ranges for age. (PT/INR and PTT)
排除标准
- •History of prior treatment with a gene therapy product, Any other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the PI, would preclude participation in the study, Ongoing veno-occlusive disease (VOD) as determined by liver ultrasound (moderate ascites and static or retrograde portal vein flow) the day before FBX-101 infusion, Presence of major congenital anomaly or any other condition that affects neurodevelopmental function, Presence of any neurocognitive deficit or brain damage not attributable to Krabbe disease, Active aspiration, Signs of active infection or disease from cytomegalovirus, adenovirus or other viruses, HIV positive, Uncontrolled and progressive bacterial or fungal infection, Presence of any contraindication for MRI, Use of any investigational product prior to study enrollment or current enrollment in another study that involves clinical interventions
研究者
相似试验
进行中（未招募）
1 期
A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with PembroEUCTR2019-002034-36-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc135
进行中（未招募）
1 期
A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with PembroEUCTR2019-002034-36-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc135
进行中（未招募）
1 期
A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with PembroAdvanced/metastatic melanomaMedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2019-002034-36-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.135
进行中（未招募）
1 期
A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with PembroEUCTR2019-002034-36-DEMerck Sharp & Dohme LLC135
进行中（未招募）
1 期
A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with PembroAdvanced/metastatic melanomaMedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2019-002034-36-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc85